市场调查报告书
商品编码
1498717
癌症 Gamma Delta T 细胞治疗的全球市场:市场机会与临床试验见解 (2030)Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 |
使用未来 T 细胞的免疫疗法长期以来一直在癌症治疗领域掀起风暴,但需要透过开发其他尖端疗法来扩大癌症免疫疗法的领域。然而,这仍然促使了其他 T 细胞受体的发现,例如 γδT 细胞和 αβT 细胞。随后,基于 γ δ T 细胞的免疫疗法被发现,基于 γ δ T 细胞的免疫疗法的开发可能成为治疗癌症以及包括病毒感染、自体免疫和发炎等其他疾病的创新疗法。治疗。
基于γ-δ T 细胞的免疫疗法的全球临床领先地位由30 种产品组成(截至2024 年6 月),其中一些产品处于临床前阶段,并需要该领域的持续研发和技术进步,其中大多数正在进行中。然而,治疗癌症和其他疾病的药物尚未进入商业市场。然而,一旦一种药物获得批准,其他基于 γδT 细胞的免疫疗法就会被推向市场,并有可能成为数百万美元的市场。
推动基于 γδT 细胞的免疫疗法市场成长的策略驱动力之一是临床前研究和临床试验的增加。在过去的十年中,全球基于 γδT 细胞的免疫疗法市场受到了一些新的、创新的和先进的竞争对手的发展的推动。例如,美国临床阶段生物技术公司Acepodia Biotech开发了两种竞争药物ACE1708和ACE2016,用于治疗表达PD-L1的实体肿瘤和表达EGFR的肿瘤。
本报告考察了全球癌症 γ δ T 细胞治疗市场,并提供了市场概况,包括其在癌症治疗中的作用、区域趋势、临床试验趋势以及进入市场的公司的竞争趋势。
Global Gamma Delta T Cell Cancer Therapy Market Opportunity & Clinical Trials Insight 2030 Report Conclusions:
After vicennium of futuristic T cells entrenched immunotherapy dominating the treatment landscape of cancer arena, there is a prerequisite to branch out cancer immunotherapy realm by developing other state-of-the-art therapies. But in spite of that, this led to discovery of other T cells receptors, such as gamma delta T cells, alpha-beta T cell and others. Consecutively, finding of gamma delta T cells based immunotherapy (also recognized as Yδ T cells), it was further pragmatic that developing gamma delta T cells based immunotherapies will aid to offer a innovatory treatment for cancer along with other disorders, including viral infections, autoimmune and inflammation.
With respect to KuicK Research statistics, the global clinical conduit of gamma delta T cells based immunotherapy comprises of 30 drugs (as of June 2024), several of which are in preclinical stage as well as majority of research and development along with technological advancement in in this sector is ongoing in the US and China region. Albeit, no drug has penetrated into the commercial market to treat cancer or other ailments; however, as soon as one drug will get approved will aid to launch other gamma delta T cells based immunotherapy into market and clenches potential to become a multimillionaire market in imminent.
One of the strategic prime movers that bestow to bourgeon the growth of gamma delta T cells based immunotherapy market is the rise in preclinical and clinical studies. Over the preceding decennium, the sphere of global gamma delta T cells based immunotherapy market has witnessed the development of several novel, innovative as well as advanced competitors. For instance, a clinical-stage biotechnology company in US, Acepodia Biotech has developed 2 contenders, ACE1708 as well as ACE2016 to treat solid tumor expressing PD-L1 accompanied with EGFR expressing tumors.
Coupled with this, the presences of various stakeholders in conjugation with investors from giant pharma companies accompanied with biotech companies, such as Bristol Myers Squibb, TC Biopharm, PersonGen BioTherapeutics, In8bio, Kiromic BioPharma, Immatics, Legend Biotech, Innate Pharma, Ever Supreme Bio Technology, Editas Medicine, CytoMed Therapeutics, Acepodia Biotech and other have bestowed to transform the treatment paradigm by developing up-to-the-minute gamma delta T cells based immunotherapy worldwide. Amid all these companies, PersonGen BioTherapeutics is the frontrunner in this segment as the company is developing 5 allogeneic UCAR- Yδ1 T cell therapy for the treatment of autoimmune, T cell malignancies and other solid tumors. The presences of giant pharmaceuticals aid to conduct multitudinous clinical trials in gamma delta T cells based immunotherapy space.
Just as importantly, an inclining market trend towards developing avant-garde global gamma delta T cells based immunotherapy, such as developing gamma-delta gene editing based immunotherapy, is gaining spotlight amid healthcare professionals. For instance, a biotech company based in Germany, Immatics has collaborated with Bristol Myers Squibb and Editas Medicine in order To syndicate gamma-delta T cell based adoptive cell therapies in addition to gene editing for the treatment of cancer.
Until now, no gamma delta T cells based immunotherapies has been approved in global market; nevertheless, it can be anticipated that a handful of gamma delta T cells therapies will be launched into the market in approaching 5 to 7 years due to the fact that many gamma delta T cells based immunotherapies have received FDA designations which aid to accelerate the approval process. For instance, ADI-001 has gained utmost breakthrough as it has received FDA fast track designation for the potential treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), in 2022, and relapsed/refractory class III or class IV lupus nephritis in June 2024. Overall, aforementioned illustrates clearly forecasts that the future of gamma delta T cells based immunotherapies will be propitious.